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Essentials  
- The response of thromboelastometry (ROTEM) parameters to therapy is unknown. 
- Prospectively recruited haemorrhaging trauma patients in 6 level-1 trauma centres in 
Europe.  
- Blood products and pro-coagulants prevent further derangement of ROTEM results, 
although effects are small. 
- ROTEM algorithms can be used to treat and monitor trauma induced coagulopathy. 
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Summary 
 
Background: Rotational Thromboelastometry (ROTEM®) can detect trauma-induced 
coagulopathy (TIC) and is used in transfusion algorithms. The response of ROTEM® to 
transfusion therapy is unknown. 
Objectives: To determine the response of ROTEM profiles to therapy in bleeding trauma 
patients. 
Patients/Methods: Prospective multicentre study in bleeding trauma patients (receiving ≥ 4 
red blood cell units). Blood was drawn on the emergency department, after administration 
of 4, 8 and 12 RBCs and 24 hours post injury. The response of ROTEM to plasma, platelets 
(PLTs), tranexamic acid (TXA) and fibrinogen products was evaluated in the whole cohort as 
well as in the subgroup of patients with ROTEM values indicative of TIC.  
Results: 309 bleeding and shocked patients were included. A mean dose of 3.8 grams of 
fibrinogen increased FIBTEMCA5 with 5.2 mm (4.1–6.3). TXA administration decreased lysis 
by 5.4 %( 4.3–6.5). PLT transfusion prevented further derangement of parameters of clot 
formation. The effect of PLTs on EXTEMCA5 values was more pronounced in patients with a 
ROTEM value indicative of TIC compared to the whole cohort. Plasma transfusion decreased 
EXTEM CT with 3.1 sec (-10–3.9) in the whole cohort and with 10.6 sec (-45–24) in the 
subgroup of patients with a ROTEM value indicative of TIC. 
Conclusion:  Effects of therapy on ROTEM values were small, but prevented further 
derangement of test results. In patients with ROTEM values corresponding to TIC, efficacy of 
PLT and plasma to correct deranged ROTEM parameters is possibly more robust. 
 
Keywords: ROTEM, haemorrhage, transfusion, trauma, viscoelastic haemostatic assay 
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Introduction 
Trauma-induced coagulopathy (TIC) develops in up to 25% of severely injured trauma 
patients, which aggravates massive hemorrhage and is associated with increased mortality 
[1, 2]. Current resuscitation practices often include an empirical balanced resuscitation 
approach with administration of red blood cells, plasma and platelets in a 1:1:1 ratio [3-5]. 
While this non-specific strategy reduces the development of dilutional coagulopathy, it may 
not correct different pre-existing forms of coagulopathy that are present in individual 
patients [6, 7]. Also, this empirical approach fails to correct TIC in recipients of large volumes 
of blood [8, 9]. Implementation of the empirical 1:1:1 strategy, often as part of massive 
transfusion protocols, has increased the amount of blood products transfused [10]. As 
transfusion is also associated with adverse outcome, including infections [11], and organ 
failure [12-15], the outcome of traumatic bleeding is probably optimal with a targeted, 
precision-medicine approach to manage TIC, leading to improved outcomes while avoiding 
unnecessary transfusion. 
This precision approach requires monitoring of effects of therapy. Clotting tests, like 
prothrombin time (PT), activated partial thromboplastin time (APTT) and platelet count have 
limited usefulness in guiding resuscitation strategy [16-18]. Viscoelastic Haemostatic Assays 
(VHA) such as thrombelastography (TEG®) or Rotational Thromboelastometry (ROTEM®) are 
rapid tests which can identify TIC in trauma patients [19-21]. A trial in which trauma patients 
were randomized to either TEG or conventional tests to guide lab-based transfusion therapy, 
showed a survival benefit for the TEG guided arm, while the amount of blood products that 
was needed was decreased [22]. These results are promising, although effects need to be 
validated in larger multicentre trials. Also, the response of VHA parameters to therapy given 
during bleeding is not known. Thereby, existing algorithms only provide threshold levels that 
trigger therapy [22-25]. In order to identify effective therapy for TIC, algorithms based on 
VHA parameters need to be refined. The aim of this study was to determine the response of 
ROTEM parameters to therapy in bleeding trauma patients. 
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Methods 
As part of a prospective multicentre observational study, termed the Activation of 
Coagulation and Inflammation in Trauma (ACIT) study (United Kingdom Clinical Research 
Network Study Portfolio, ID: 5637), this study was performed in 6 European level-1 trauma 
centres; London, Oslo, Copenhagen, Oxford, Cologne and Amsterdam, which are members 
of the International Trauma Research Network (INTRN). All adult trauma patients (age ≥18 
years) who required a full trauma team activation, who received at least 4 units of RBCs 
within 24 hours and who were still alive after 24 hours, were recruited between January 
2008 and April 2015. Patients who received >2 L intravenous fluids pre-hospital, who arrived 
>2 hours after injury in the Emergency Department (ED), who were transferred from other 
hospitals and patients who had burns covering more than 5% of the total body surface area, 
were not eligible. Patients were retrospectively excluded if they declined to give informed 
consent, were taking anticoagulant medications other than aspirin (<650mg/day), had 
moderate or severe liver disease (Child's classification B or C3), had a known bleeding 
diathesis, had no ROTEM measurements available or died within 24 hours post-injury.  
Written informed consent was obtained from each patient. When the patient was 
unconscious, written informed consent was obtained from a legal representative. This study 
was conducted according to the Statement of the Declaration of Helsinki and performed 
after approval by the local ethics committees.  
The following data were collected prospectively to a centralized database: data on patient 
demographics, time of injury, trauma mechanism, vital signs and laboratory tests up to 24 
hours’ post-injury, Injury Severity Score (ISS), Abbreviated Injury Scale Score (AIS), 24-hours 
and 28-day mortality, total fluids (crystalloids, colloids, hypertonic saline), amount of red 
blood cell units (RBCs), plasma and platelet units (PLTs), anti-fibrinolytic (TXA) and pro-
coagulant agents (fibrinogen concentrates, cryoprecipitate).  
 
Blood sampling and ROTEM® assays 
Blood was drawn and collected in citrated tubes immediately on arrival in the ED and at 24 
hours post injury. Additionally, during resuscitation with blood component therapy, blood 
samples were drawn after administration of 4, 8 and 12 RBCs. The dose of plasma and 
platelets given in the intervals between blood draws was also prospectively collected. Two 
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ROTEM® assays (EXTEM and FIBTEM) were performed by trained personnel after blood 
samples were taken. These assays were chosen based on our previous results in determining 
threshold values for TIC [26]. Within each assay, 6 ROTEM parameters were analysed; the 
clotting time (CT), the clot amplitude after 5 minutes (CA5), the clot amplitude after 10 
minutes (CA10), the angle of tangent at 20 mm amplitude (alpha angle), the maximum clot 
firmness (MCF) and the lysis index of the clot after 30 minutes (LY30).  
In this same patient cohort, we recently determined ROTEM thresholds with a high detection 
rate for TIC, as measured on ED arrival [26]. FIBTEM CA5 had the highest diagnostic 
performance to detect a low fibrinogen level (< 2.0 g/dl), with a cut-off value of < 10 mm. 
EXTEM-FIBTEM CA5 had the highest diagnostic performance to detect low platelet count (< 
100 x109/L), with a threshold of 30 mm. EXTEM LY30 below 85% was associated with a 
sudden increase in red blood cell requirements and mortality. EXTEM CA5 had the highest 
diagnostic performance to detect coagulopathy as defined by an INR >1.2, with a CA5 
threshold of 40 mm. The response of ROTEM parameters to treatment was investigated in 
all bleeding patients, as well as in those patients with a ROTEM profile corresponding to TIC 
upon ED arrival. The number of PLT units was corrected for the number of pooled donors, as 
this differs between centres.  
The effect of plasma and platelet therapy on ROTEM parameters was analysed by relating 
the therapy given within a time interval to changes in ROTEM results in the following 
measurement. These intervals are baseline – 4 RBC time point, 4 RBC – 8 RBC time point and 
8 RBC - 12 RBC time point. This approach was chosen because VHA parameters change 
rapidly in response to blood products. To describe the effect of TXA and fibrinogen products 
on ROTEM VHA profiles, the delta between baseline and 24 hour measurements was used. 
Intervals in which a ROTEM value was missing and the delta for ROTEM values could hence 
not be calculated, were left out. This resulted in a variable amount of intervals that could be 
evaluated. There was no loss to follow-up data of 28 day mortality. Other outcome data 
were not gathered as the denominator of measurements are intervals and not patients. 
 
Transfusion strategy 
In all trauma centres, issuing of blood products, anti-fibrinolytic and pro-coagulant agents by 
the blood bank was performed through locally implemented massive transfusion protocols 
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(MTP). In most centres, the MTP was activated for patients with a systolic blood pressure 
<90 mmHg with inadequate response to fluid administration and suspicion of ongoing 
bleeding. Centres empirically applied blood products in a fixed ratio. Administration of 
tranexamic acid (TXA), followed by a continuous infusion over 8 hours, was used as a 
principle component of the MTP in all centres. Cryoprecipitate was used in London, Oxford 
and Copenhagen, whereas Oslo, Cologne and Amsterdam used fibrinogen concentrates. The 
trigger for these concentrated fibrinogen products differed between centres from a 
fibrinogen level ≤1.0 g/L to ≤2.0 g/L. Centres were restrictive in the use of fluids, but there 
was no shared protocol on fluid management. Differences in protocols have been described 
before [27]. 
 
Statistics 
Sample size was not prespecified in this exploratory study, as ROTEM responses to therapy 
have not been described before. Descriptives of the groups are given in tables and expressed 
as mean and standard deviation if normally distributed, whereas not normally distributed 
data are expressed as median and interquartile ranges. Categorical data were presented as 
frequencies and percentages. To test for differences in patient characteristics and ROTEM 
profiles, the Student`s T-test and the Mann-Whitney U tests were used. Categorical variables 
were compared using the Chi-square test. For multiple comparisons, a one way ANOVA was 
used. A p-value <0.05 was considered to be statistically significant.    
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Results 
In total, 309 patients were transfused with ≥4 RBCs for whom ROTEM profiles were available 
(characteristics in Table 1). Most patients had sustained a blunt trauma, were in shock and 
were coagulopathic, as reflected by a prolonged mean INR and decreased levels of 
fibrinogen. The mean baseline ROTEM variables were mostly within the reference values as 
provided by the manufacturer (Table 2). All measurements together yielded 426 time 
intervals in which the effect of transfusion strategy on the ROTEM profiles could be 
determined, although the amount of intervals available for analysis varied per treatment and 
per test.  
 
ROTEM response to treatment with fibrinogen 
Of the 309 patients, 119 patients (39%) received fibrinogen products, containing a mean of 
3.8 (SD 1.2) grams of fibrinogen. Patients administered fibrinogen products were more 
severely injured as reflected by a higher ISS and they were more acidotic compared to those 
not receiving fibrinogen (Sup Table 1). Also, baseline fibrinogen levels were lower in patients 
receiving fibrinogen. Despite this, in the whole group of patients receiving fibrinogen, 
administration of fibrinogen products resulted in a greater increase in FIBTEM parameters 
when compared to patients not receiving fibrinogen (Table 3). In patients with a ROTEM 
profile known to correspond with low fibrinogen (FIBTEM CA5<10 mm) [26], the response to 
therapy was the same as in the whole cohort receiving fibrinogen. 
 
ROTEM response to treatment with platelets 
Of the 309 patients, 212 (69%) received PLTs. Patient administered PLTs had lower baseline 
platelet counts then those not receiving PLTs, although platelet count was normal in most 
patients (Sup Table 2). In all patients, EXTEM parameters of clot formation worsened during 
the course of bleeding and treatment (Table 4). In the whole group of patients receiving 
PLTs, EXTEM values were higher during management when compared to those not receiving 
PLTs, although not reaching statistical significance. In patients with a ROTEM profile known 
to correspond to low platelet levels [26], the decrease in EXTEM CA5 was significantly less 
when compared to those not receiving therapy.  
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ROTEM response to treatment with plasma 
Of the 309 patients, 280 (91%) patients received plasma. The patients receiving plasma were 
more shocked, as reflected by a higher heart rate and lower base excess (Sup Table 3). In the 
whole group of patients receiving plasma, plasma transfusion significantly reduced EXTEM 
CT with a mean of 3.1 sec compared to patients not receiving plasma (Table 5), in whom 
EXTEM CT prolonged during bleeding and management. In those patients with an EXTEM CT 
known to correspond to coagulopathy, ROTEM responses to therapy were more 
pronounced, with EXTEM CT reduction of 10.6 sec, although statistical significance was not 
reached due to a wide confidence interval. Of note, the amount of intervals was small. 
 
ROTEM response to treatment with tranexamic acid 
Use of TXA was not registered in 19 patients. Of the remaining 290 patients, 112 patients 
(39%) received TXA. Patients administered TXA were more severely injured as reflected by a 
higher ISS and were more shocked and more acidotic compared to those not receiving TXA 
(Sup Table 4). In the whole group of patients receiving TXA, administration of TXA resulted in 
a greater improvement of lysis and FIBTEM parameters when compared to patients not 
receiving TXA (Table 6). In those patients with a LY30 suggestive of hyper fibrinolysis [26], 
the response to therapy was the same as in the whole cohort receiving TXA.  
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Discussion 
Results indicate that during management of patients with traumatic bleeding, almost all of 
the ROTEM profiles show further deterioration. This study suggests that the effect of 
treatment with transfusion products and pro-coagulant therapy with the aim to improve 
deranged ROTEM parameters can be monitored during traumatic hemorrhage. Fibrinogen, 
plasma, PLTs and TXA improve ROTEM parameters of clot formation and firmness and 
decrease clot lysis. Although effects can be described as modest, it must be noted that these 
improvements were detected during ongoing resuscitation of hemorrhage. In the subgroup 
of patients with ROTEM threshold values that were previously identified to correspond to 
coagulopathy (i.e. low fibrinogen levels, thrombocytopenia, increased fibrinolysis and/or an 
INR>1.2), the efficacy of plasma and PLTs to correct ROTEM parameters was possibly more 
robust when compared to the whole bleeding population receiving treatment. 
 
We previously showed that in the same cohort of patients, administration of fibrinogen did 
not result in correction of low fibrinogen levels in patients who are actively bleeding [28]. 
Here, we show that a mean dose of fibrinogen of 3.8 grams improves EXTEM CA5 levels with 
5 mm. Thereby, this ROTEM marker may guide fibrinogen dosing in traumatic bleeding. Of 
note, it was shown before that low fibrinogen levels are associated with adverse outcome in 
traumatic hemorrhage [29-31]. Unfortunately, we cannot provide further analysis of the 
effect of fibrinogen dose on correction of ROTEM, because the exact timing of fibrinogen 
administration was not noted.  
For monitoring of the effect of TXA, there are currently no conventional clotting tests 
available at the bedside. In this study, 1 gram of TXA improved all early markers of clot 
formation and decreased markers of lysis. It was shown before that TXA administration is 
associated with good outcome [28]. Taken together, results indicate that monitoring of the 
effect of pro-coagulant therapy on TIC is possible during management of bleeding trauma 
patients. 
Plasma transfusion reduced the EXTEM CT, whereas in patients not receiving plasma, EXTEM 
CT further prolonged during bleeding. As EXTEM CT is a marker of TIC that occurs very early 
during ROTEM testing, results suggest that EXTEM CT may guide the specific need for 
increased dose of plasma. Of note, as low fibrinogen levels affect the whole coagulation and 
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fibrinogen will also reduce EXTEM CT, one may first consider correcting a fibrinogen 
deficiency with fibrinogen concentrates prior to considering additional plasma. 
In severe injury, a drop in the platelet count occurs late [32]. Thereby, the platelet count per 
se may not be a useful transfusion trigger. In this study in which most patients had normal 
PLT counts, the derangement of EXTEM parameters of clot formation was less in patients 
receiving PLT transfusion, which may suggest that EXTEM parameters are more useful then 
platelet counts in monitoring effects of therapy.  
 
Previously, in the same cohort of patients, threshold ROTEM values corresponding to TIC and 
adverse outcome were identified [26]. With these values, algorithms for guidance of 
management of TIC were constructed.  This study aims to provide follow-up data. Here, we 
show that in bleeding patients, transfusion of plasma and PLTs in those patients with ROTEM 
levels that would trigger therapy according to threshold values corresponding to TIC [26], 
show more improvement of ROTEM values then in the whole group of bleeding patients. 
However, the effect of plasma did not reach statistical significance, likely due to a loss of 
data points. Whether use of the algorithm to guide therapy results in better outcome while 
reducing unnecessary transfusion, is currently under investigation in a randomized 
controlled trial [33]. 
 
Limitations to this study should be acknowledged. Studies were performed in patients with 
ongoing bleeding, in which the rate of bleeding most likely affected ROTEM results, but 
which is impossible to account for. Another issue is that blood products were administered 
together, rendering it impossible to attribute an effect on ROTEM value to a specific therapy. 
However, these issues reflects real life clinical practice. Another important limitation is that 
we were not able to report on ROTEM changes in response to different doses of fibrinogen 
and TXA. This remains an area which needs to be explored. Also, exsanguinating patients 
were excluded in order to provide for follow-up samples. Thereby, results may not apply to 
the most severely bleeding patients. Also, as most patients in this study had sustained blunt 
injury, it remains to be determined whether response to therapy is the same in patients with 
penetrating injury. Lastly, transfusion protocols differ between centers, which is a limitation 
to this observational study. 
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Conclusion 
Viscoelastic haemostatic assays such as ROTEM® can be used for monitoring of treatment for 
TIC during ongoing traumatic hemorrhage. In patients with ROTEM threshold values known 
to correspond to coagulopathy, the efficacy of plasma and PLTs was possibly clearer than in 
the whole bleeding population, suggesting that ROTEM-based algorithms can be used to 
treat and monitor TIC. 
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Table 1. Baseline characteristics and outcome of patients receiving ≥ 4 RBCs  
 N=309 
Age, years 44.8 (1.1) 
Gender, male 73% 
Trauma mechanism, blunt 83% 
ISS  29.1 (0.7) 
SBP, mmHg  106.2 (1.9) 
Heart rate, bpm  110.2 (1.7) 
Lactate, mmol/L 5.1 (4.4) 
GCS  10.8 (0.3) 
Hb, g/dL  12.5 (0.1) 
Platelet count, x10^9/L  214.2 (4.1) 
INR 1.22 (0.1) 
Fibrinogen, g/L  1.9 (0.1) 
Base Excess, mEqL -7.5 (0.4) 
28 day mortality 22.9 % 
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Table 2. Baseline ROTEM variables of patients receiving ≥ 4 RBCs  
 N=309 
EXTEM CT  (sec) 70.3 (2.0) 
EXTEM CA5 (mm) 39.7 (0.6) 
EXTEM CA10 (mm) 49.6 (0.7) 
EXTEM MCF (mm) 58.5 (0.6) 
EXTEM α angle (°) 67.9 (0.6) 
EXTEM LY30 (%) 96.9 (1.0) 
EXTEM CFT (sec) 136.4 (10.9) 
FIBTEM CA5 (mm) 10.0 (0.3) 
FIBTEM CA10 (mm) 10.9 (0.3) 
FIBTEM MCF (mm) 12.7 (0.4) 
FIBTEM α angle (°) 61.7 (0.5) 
FIBTEM LY30 (%) 94.9 (1.0) 
Data are mean and SE of the mean or % of total 
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Table 3. ROTEM response to fibrinogen 
 All patients  
receiving fibrinogen 
 
Patients with FIBTEM 
CA5<10 receiving 
fibrinogen 
 
Patients not receiving 
fibrinogen 
 N=119 intervals N=82 intervals N=190 intervals 
FIBTEM CA5 (mm) 5.0 (3.9 to 6.1)* 5.1 (3.8 to 6.4)* 2.4 (1.5 to 3.3) 
FIBTEM CA10 (mm) 5.5 (4.2 to 6.8)* 5.5 (4.1 to 7.0)* 2.8 (1.8 to 3.7) 
FIBTEM MCF (mm) 5.8 (4.1 to 7.4)* 5.8 (3.8 to 7.9)* 2.1 (0.8 to 3.6) 
FIBTEM α angle (°) 8.4 (5.3 to 11.6)* 8.4 (5.4 to 11.4)* 3.2 (1.0 to 5.5) 
*=P<0.05 versus not receiving fibrinogen. Response of ROTEM was determined in the 
interval between baseline and t=24 hours. 
 
Table 4. ROTEM response to platelets 
 All patients  
receiving platelets 
 
Patients with EXTEM 
CA5 – FIBTEM CA5 < 
30 receiving platelets 
 
Patients not receiving 
platelets 
 N=137 intervals N=25 intervals N=103 intervals 
EXTEM CA5 (mm) -1.55 (-4.48 to 1.37) 0.74 (-4.77 to 6.25)* -4.39 (-6.06 to -2.72) 
EXTEM CA10 (mm) -1.14 (-4.24 to 1.95) 0.53 (-5.6 to 6.66) -4.13 (-5.96 to -2.3) 
EXTEM MCF (mm) -0.11 (-2.77 to 2.55) 1.45 (-3.92 to 6.81) -2.67 (-4.58 to -0.75) 
EXTEM α angle (°) 0.43 (-2.96 to 3.82) 1.18 (-5.8 to 8.16) -3.34 (-5.07 to -1.62) 
*=P<0.05 versus not receiving platelets. Response of ROTEM was determined in intervals 
during resuscitation therapy. 
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Table 5. ROTEM response to plasma 
 All patients  
receiving plasma 
 
Patients with EXTEM 
CT>80 while CA5>40 
receiving plasma 
 
Patients not 
receiving plasma 
 N=117 intervals N=17 intervals N=42 intervals 
EXTEM CT (sec) -3.1 (-10.0 to 3.9)* -10.6 (-45.7 to 24.2) 10.8 (-0.8 to 22.3) 
EXTEM MCF (mm) -1.7 (-3.3 to -0.1) -5.2 (-12.1 to 1.7) -4.1 (-7.9 to -0.4) 
EXTEM CFT (sec) 19.5 (4.7 to 34.3) 30.31 (1.2 to 59.4) 37.4 (5.4 to 69.4) 
*=P<0.05 versus not receiving plasma. Response of ROTEM was determined in intervals 
during resuscitation therapy. 
 
 
Table 6. ROTEM  response to TXA  
 All patients  
receiving TXA 
 
Patients with 
EXTEMLY30<85% 
receiving TXA 
 
Patients not 
receiving TXA 
 N=76 intervals N=34 intervals N=170 intervals 
EXTEM LY30 (%) 5.4 (4.3 to 6.5)* 5.4 (4.1 to 6.7)* 3.0 (2.1 to 3.9) 
FIBTEM CA5 (mm) 6.0 (4.8 to 7.3)* 6.1 (4.6 to 7.5)* 3.6 (2.6 to 4.5) 
FIBTEM CA10 (mm) 6.1 (4.4 to 7.9)* 6.1 (3.6 to 8.6)* 3.2 (1.7 to 4.6) 
FIBTEM MCF (mm) 8.1 (5.3 to 10.9)* 8.1 (5.0 to 11.2)* 3.3 (0.8  to 5.8) 
FIBTEM α angle (°) 5.4 (4.4 to 6.5)* 5.4 (4.1 to 6.7)* 3.0 (2.1 to 3.9) 
FIBTEM LY30 (%) 6.0 (4.8 to 7.3)* 6.0 (4.5 to 7.5)* 3.6 (2.6 to 4.5) 
*=P<0.05 versus not receiving TXA. Response of ROTEM was determined in the interval 
between baseline and t=24 hours. 
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